Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.15 USD
-0.06 (-4.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 7:54 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Income Statements
Fiscal Year end for Aclaris Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 31 | 30 | 7 | 6 | 4 |
Cost Of Goods | 18 | 12 | 5 | 5 | 4 |
Gross Profit | 13 | 18 | 2 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 111 | 108 | 92 | 52 | 111 |
Income After Depreciation & Amortization | -97 | -90 | -90 | -51 | -111 |
Non-Operating Income | 9 | 3 | -1 | 0 | -50 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -89 | -87 | -91 | -51 | -161 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -88 | -87 | -91 | -51 | -161 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -88 | -87 | -91 | -51 | -161 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -96 | -89 | -89 | -50 | -86 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 25 |
Income After Depreciation & Amortization | -97 | -90 | -90 | -51 | -111 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 69.81 | 65.21 | 56.73 | 42.54 | 41.32 |
Diluted EPS Before Non-Recurring Items | -1.55 | -1.33 | -1.60 | -1.20 | -2.25 |
Diluted Net EPS (GAAP) | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 |
Fiscal Year end for Aclaris Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2.77 | 2.40 | 17.57 | 9.28 | 1.87 |
Cost Of Goods | 1.91 | 1.84 | 6.43 | 8.19 | 1.59 |
Gross Profit | 0.86 | 0.56 | 11.14 | 1.09 | 0.28 |
SG&A, R&D, and Dept/Amort Expenses | 13.71 | 19.49 | 15.19 | 32.67 | 32.10 |
Income After SG&A, R&D, and Dept/Amort Expenses | -12.85 | -18.93 | -4.05 | -31.58 | -31.82 |
Non-Operating Income | 1.87 | 1.99 | 2.19 | 2.32 | 2.25 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -10.99 | -16.94 | -1.86 | -29.26 | -29.57 |
Income Taxes | 0.00 | 0.00 | -0.37 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.99 | -16.94 | -1.49 | -29.26 | -29.57 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -10.99 | -16.94 | -1.49 | -29.26 | -29.57 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 71.29 | 71.08 | 70.87 | 70.81 | 70.63 |
Diluted EPS Before Non-Recurring Items | -0.15 | -0.24 | -0.30 | -0.41 | -0.42 |
Diluted Net EPS (GAAP) | -0.15 | -0.24 | -0.02 | -0.41 | -0.42 |